Exhibit 99

Pall Corporation Reports Strong First Quarter Sales and Operating Profit Growth

EAST HILLS, N.Y.– Pall Corporation (NYSE: PLL – News) today reported sales and earnings results for the first quarter ended October 31, 2006.

First Quarter Results

Sales for the quarter were $499.3 million, up 16% compared with the same quarter last year. Net earnings were $24.4 million, or $0.20 per share. Earnings on a pro forma basis, excluding charges principally related to the Company's cost reduction initiatives, were $0.29 per share as compared to $0.20 per share in the same quarter last year. Foreign currency translation increased sales by 2% with minimal impact on earnings.

Eric Krasnoff, Chairman and CEO, said, "Pall's Total Fluid Management(sm) approach to the market continues to drive sales in the Life Sciences and Industrial segments. Our base consumables and systems businesses are both on track. Orders remained strong and we have again entered the next quarter with a record backlog.

The realignment of Pall Corporation into two integrated businesses, Industrial and Life Sciences, is now complete. Our new financial presentation format reflects this and provides greater visibility into Pall for investors."

Mr. Krasnoff added, "We are investing in sales and marketing, customer support and product development programs. At the same time we are working assiduously to reduce cost. Selling, general and administrative expenses continued to decrease as a percentage of sales, reaching 31.5% in the quarter. Gross margins present a tougher challenge. Cost of Sales is the major target of our cost reduction programs and facilities rationalization initiative. These activities are proceeding to plan and we are confident of success."

Consolidated – First Quarter Financial Summary

	OCT. 31, 2006		OCT. 31, 2005		% CHANGE IN LOCAL CURRENCY
Sales	$	499,288	$	431,162		14.0
Net Earnings	$	24,434	$	25,110
Diluted EPS	$	0.20	$	0.20
Pro Forma Diluted EPS	$	0.29	$	0.20
Life Sciences – First Quarter Summary

Sales:	OCT. 31, 2006		% CHANGE		% CHANGE IN LOCAL CURRENCY
Medical	$	103,512		8.8		7.4
BioPharmaceuticals		89,490		21.3		18.6
Total Life Sciences segment	$	193,002		14.2		12.3

			% OF SALES
Gross profit	$	95,226		49.3	%
Operating profit	$	29,188		15.1	%

1

Mr. Krasnoff continued, "BioPharmaceuticals sales increased 18.6% with 16% growth in consumables. This reflects a high level of drug production, along with investment in new capacity by the biotechnology sector. Medical sales increased 7.4%, with growth in the Blood Filtration and Hospital portions of the business in the Western Hemisphere and Europe.

Gross margin improved to 49.3% compared with 48.8% last year. Selling, general and administrative expenses improved to 30.3%. Operating profit increased 29.3% and operating margin improved to 15.1% from 13.4% last year."

Industrial – First Quarter Summary

Sales:	OCT. 31, 2006		% CHANGE		% CHANGE IN LOCAL CURRENCY
General Industrial	$	175,073		13.9		11.4
Aerospace and Transportation		60,332		9.4		7.4
Microelectronics		70,881		32.7		31.7
Total Industrial segment	$	306,286		16.8		14.7

			% OF SALES
Gross profit	$	128,873		42.1	%
Operating profit	$	33,289		10.9	%

"Pall Industrial produced strong top-line sales growth," Mr. Krasnoff commented. "Within the segment, General Industrial sales grew 11.4% driven by strong system sales growth into energy related markets. Microelectronics sales were up 31.7%. New product sales into the consumer electronics market are making an impact. Aerospace and Transportation sales increased 7.4% driven by Military Aerospace sales in the Western Hemisphere.

Gross margins were reduced due to product mix, including the very strong sales performance of the systems business. Selling, general and administrative expenses improved by 3.9% as a percentage of sales to 29.1% reflecting top line leverage and cost reduction initiatives. Operating profit increased 24.3% and operating margin improved to 10.9% from 10.2% last year."

Conference Calls

Tomorrow, December 5, 2006, at 8:30 am ET, Pall Corporation will host its quarterly earnings conference call.

In addition, a conference call providing a detailed discussion of changes to the Company's financial reporting structure will follow the earnings call, at 11:00 am ET.

The calls will be webcast and individuals can access these webcasts from the home page of the Company's website, at www.pall.com/investor. Listening to the webcasts requires speakers and Microsoft Windows Media Player software. The webcast of the quarterly earnings call will be archived for 30 days and the webcast of the call discussing the changes to the Company's financial reporting structure will be archived for 90 days.

2

About Pall Corporation:

Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, municipal and industrial water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2006 were $2.0 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. For more information visit Pall at www.pall.com.

Forward Looking Statements:

Results for first quarter ended October 31, 2006 are preliminary until the Company's Form 10-Q is filed with the Securities and Exchange Commission. Forward-looking statements contained in this and other written and oral reports are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. All statements regarding future performance, earnings projections, earnings guidance, events or developments are forward-looking statements. Such risks and uncertainties include, but are not limited to: changes in product mix and product pricing particularly as we expand our systems business in which we experience significantly longer sales cycles and less predictable revenue with no certainty of future revenue streams from related consumable product offerings and services; increases in costs of manufacturing and operating costs including energy and raw materials; the Company's ability to achieve the savings anticipated from cost reduction and margin improvement initiatives including the timing of completion of the facilities rationalization initiative; fluctuations in foreign currency exchange rates and interest rates; regulatory approval and market acceptance of new technologies; changes in business relationships with key customers and suppliers including delays or cancellations in shipments; success in enforcing patents and protecting proprietary products and manufacturing techniques; successful completion or integration of acquisitions; domestic and international competition in the Company's global markets; and global and regional economic conditions and legislative, regulatory and political developments. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them.

Management uses certain non-GAAP measurements to assess Pall's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing Pall's financial position and results of operations. Pall has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations.

3

PALL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(AMOUNTS IN THOUSANDS)

	OCT. 31, 2006		JUL. 31, 2006
Assets:
Cash and cash equivalents	$	360,595	$	317,657
Accounts receivable		469,102		517,632
Inventories		424,051		408,273
Other current assets		143,248		133,419
Total current assets		1,396,996		1,376,981
Property, plant and equipment, net		608,868		620,979
Other assets		553,715		554,898
Total assets	$	2,559,579	$	2,552,858
Liabilities and Stockholders' Equity:
Short-term debt	$	49,259	$	63,382
Accounts payable, income taxes and other current liabilities		458,208		467,434
Total current liabilities		507,467		530,816
Long-term debt		641,109		640,015
Deferred taxes and other non-current liabilities		204,096		203,331
Total liabilities		1,352,672		1,374,162
Stockholders' Equity		1,206,907		1,178,696
Total liabilities and stockholders' equity	$	2,559,579	$	2,552,858

4

PALL CORPORATION
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
(Amounts in thousands, except per share data)

	FIRST QUARTER ENDED
	OCT. 31, 2006			OCT. 31, 2005
Net Sales	$	499,288		$	431,162
Cost of sales		275,616	(a)		229,485	(b)
Gross profit		223,672			201,677
Selling, general and administrative expenses		157,375			149,707
Research and development		14,234			13,066
Earnings before restructuring and other charges/(gains), net ("ROTC"), interest expense, net and income taxes		52,063			38,904
ROTC		17,088	(a)		(50	)(b)
Interest expense, net		5,786			5,739
Earnings before income taxes		29,189			33,215
Provision for income taxes		4,755			8,105
Net earnings	$	24,434		$	25,110
Earnings per share:
Basic	$	0.20		$	0.20
Diluted	$	0.20		$	0.20
Average shares outstanding:
Basic		122,812			124,887
Diluted		123,801			125,690
Net earnings as reported	$	24,434		$	25,110
ROTC and one-time purchase accounting adjustment, after pro forma tax effect		11,061			171
Pro forma earnings	$	35,495		$	25,281
	$	0.20		$	0.20
Diluted earnings per share as reported ROTC and one-time purchase accounting adjustment, after pro forma tax effect		0.09			—
Pro forma diluted earnings per share	$	0.29		$	0.20

(a)

ROTC includes $13,581 (7 cents per share, after pro forma tax effect) primarily comprised of severance costs and an impairment charge for the planned disposal and early retirement of a building and certain other long-lived assets related to the Company's cost reduction programs, including its facility rationalization initiative. In addition, the quarter includes other charges of $3,507 (2 cents per share, after pro forma tax effect), primarily related to an increase in environmental reserves. Cost of sales includes $427 comprised of incremental depreciation recorded in conjunction with the Company's facilities rationalization initiative.

(b)

ROTC includes a gain of $1,806 (1 cent per share, after pro forma tax effect) on the sale of an investment partly offset by severance and other costs of $1,756 ( 1 cent per share, after pro forma tax effect) primarily related to the Company's business realignment. Included in cost of sales is a charge of $311, related to a one-time purchase accounting adjustment to record, at market value, inventory acquired from BioSepra. This resulted in a $2,431 increase in acquired inventories in accordance with SFAS No. 141, "Business Combinations" and a charge to cost of sales in the quarter concurrent with the sale of a portion of the underlying inventory.

5

PALL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(Unaudited)
(AMOUNTS IN THOUSANDS)

	OCT. 31, 2006				OCT. 31, 2005
Net cash provided by operating activities	$	72,092		$	31,470
Investing activities:
Capital expenditures		(13,829	)		(21,636	)
Other		1,693			(4,638	)
Net cash used by investing activities		(12,136	)		(26,274	)
Financing activities:
Dividends paid		(13,436	)		(12,434	)
Notes payable and long-term borrowings		(14,192	)		19,420
Purchase of treasury stock		(3,553	)		(5,750	)
Other		14,096			9,587
Net cash (used)/provided by financing activities		(17,085	)		10,823
Cash flow for period		42,871			16,019
Cash and cash equivalents at beginning of year		317,657			164,928
Effect of exchange rate changes on cash		67			(1,259	)
Cash and cash equivalents at end of period	$	360,595		$	179,688

6

PALL CORPORATION
SUMMARY STATEMENT OF OPERATING PROFIT BY SEGMENT
(Unaudited)
(DOLLAR AMOUNTS IN THOUSANDS)

FIRST QUARTER ENDED	OCT. 31, 2006			OCT. 31, 2005
Life Sciences
Sales	$	193,002		$	168,947
Cost of sales (a)		97,776			86,570
Gross profit		95,226			82,377
% of sales		49.3	%		48.8	%
Selling, general and administrative expenses		58,392			52,996
Research and development		7,646			6,814
Operating profit	$	29,188		$	22,567
% of sales		15.1	%		13.4	%
Industrial
Sales	$	306,286		$	262,215
Cost of sales		177,413			142,604
Gross profit		128,873			119,611
% of sales		42.1	%		45.6	%
Selling, general and administrative expenses		88,996			86,578
Research and development		6,588			6,252
Operating profit	$	33,289		$	26,781
% of sales		10.9	%		10.2	%
CONSOLIDATED:
Operating profit	$	62,477		$	49,348
General corporate expenses		(9,987	)		(10,133	)
Earnings before ROTC, interest expense, net and income taxes (a)		52,490			39,215
ROTC (a)		(17,515	)		(261	)
Interest expense, net		(5,786	)		(5,739	)
Earnings before income taxes	$	29,189		$	33,215

(a) Included in ROTC for the purpose of evaluation of segment profitability are other adjustments recorded in cost of sales. For the three months ended October 31, 2006, such adjustments include incremental depreciation of $427 recorded in conjunction with the Company's facility rationalization initiative. For the three months ended October 31, 2005, such adjustments include a charge of $311 related to a one-time purchase accounting adjustment to record at market value, inventory acquired from BioSepra. This resulted in an $2,431 increase in acquired inventories in accordance with SFAS No. 141 "Business Combinations" and a charge to cost of sales in the quarter concurrent with the sale of a portion of the underlying inventory.

7

PALL CORPORATION
SUPPLEMENTAL SEGMENT SALES INFORMATION BY MARKET AND GEOGRAPHY
(Unaudited)
(DOLLAR AMOUNTS IN THOUSANDS)

SALES FIRST QUARTER ENDED	OCT. 31, 2006		OCT. 31, 2005		% CHANGE		% CHANGE IN LOCAL CURRENCY
Life Sciences
By Market:
Medical	$	103,512	$	95,147		8.8		7.4
BioPharmaceuticals		89,490		73,800		21.3		18.6
Total Life Sciences	$	193,002	$	168,947		14.2		12.3
By Geography:
Western Hemisphere	$	84,196	$	76,081		10.7		10.5
Europe		84,672		69,581		21.7		16.6
Asia		24,134		23,285		3.6		5.1
Total Life Sciences	$	193,002	$	168,947		14.2		12.3
Industrial
By Market:
General Industrial (a)	$	175,073	$	153,671		13.9		11.4
Aerospace and Transportation (a)		60,332		55,136		9.4		7.4
Microelectronics		70,881		53,408		32.7		31.7
Total Industrial	$	306,286	$	262,215		16.8		14.7
By Geography:
Western Hemisphere	$	88,966	$	78,554		13.3		12.9
Europe		119,433		102,107		17.0		12.1
Asia		97,887		81,554		20.0		19.7
Total Industrial	$	306,286	$	262,215		16.8		14.7

(a) Certain prior year amounts have been reclassified to conform to the current year presentation.

8

PALL CORPORATION
SUMMARY STATEMENT OF OPERATING PROFIT BY SEGMENT
Restated Fiscal Year 2006 By Quarter
(Unaudited)
(DOLLAR AMOUNTS IN THOUSANDS)

	Q1			Q2			Q3			Q4
	OCT. 31, 2005			JAN. 31, 2006			APRIL 30, 2006			JULY 31, 2006			Total Year 2006
Life Sciences
Sales	$	168,947		$	187,867		$	205,937		$	233,554		$	796,305
Cost of sales (a)		86,570			95,265			103,185			116,204			401,224
Gross profit		82,377			92,602			102,752			117,350			395,081
% of sales		48.8	%		49.3	%		49.9	%		50.2	%		49.6	%
Selling, general and administrative expenses		52,996			56,356			54,159			61,543			225,054
% of sales		31.4	%		30.0	%		26.3	%		26.4	%		28.3	%
Research and development		6,814			8,697			7,625			8,452			31,588
Operating profit	$	22,567		$	27,549		$	40,968		$	47,355		$	138,439
% of sales		13.4	%		14.7	%		19.9	%		20.3	%		17.4	%
Industrial
Sales	$	262,215		$	290,569		$	304,044		$	363,697		$	1,220,525
Cost of sales (a)		142,604			157,158			167,870			202,227			669,859
Gross profit		119,611			133,411			136,174			161,470			550,666
% of sales		45.6	%		45.9	%		44.8	%		44.4	%		45.1	%
Selling, general and administrative expenses		86,578			93,564			92,880			101,265			374,287
% of sales		33.0	%		32.2	%		30.5	%		27.8	%		30.7	%
Research and development		6,252			5,701			6,886			6,944			25,783
Operating profit	$	26,781		$	34,146		$	36,408		$	53,261		$	150,596
% of sales		10.2	%		11.8	%		12.0	%		14.6	%		12.3	%
CONSOLIDATED:
Operating profit	$	49,348		$	61,695		$	77,376		$	100,616		$	289,035
General corporate expenses		(10,133	)		(9,216	)		(10,368	)		(11,972	)		(41,689	)
Earnings before ROTC, interest expense, net and income taxes (a)		39,215			52,479			67,008			88,644			247,346
ROTC (a)		(261	)		(3,931	)		(7,646	)		(2,155	)		(13,993	)
Interest expense, net		(5,739	)		(5,642	)		(5,091	)		(6,505	)		(22,977	)
Earnings before income taxes	$	33,215		$	42,906		$	54,271		$	79,984		$	210,376

(a) Included in ROTC for the purpose of evaluation of segment profitability are other adjustments of $1,667 recorded in cost of sales; $769 related to incremental depreciation recorded in conjunction with the Company's facility rationalization initiative and $898 related to a one-time purchase accounting adjustment to record at market value, inventory acquired from Biosepra. This resulted in a $2,431 increase in acquired inventories in accordance with SFAS No. 141 and a charge to cost of sales concurrent with the sale of a portion of the underlying inventory.

9

PALL CORPORATION
INDUSTRIAL SEGMENT SALES INFORMATION BY MARKET
Restated Fiscal Year 2006 By Quarter
(Unaudited)
(DOLLAR AMOUNTS IN THOUSANDS)

	Q1		Q2		Q3		Q4
	OCT. 31, 2005		JAN. 31, 2006		APRIL 30, 2006		JULY 31, 2006		Total Year 2006
Industrial
By Market:
General Industrial	$	153,671	$	171,876	$	176,043	$	218,015	$	719,605
Aerospace and Transportation		55,136		56,563		58,524		72,401		242,624
Microelectronics		53,408		62,130		69,477		73,281		258,296
Total Industrial	$	262,215	$	290,569	$	304,044	$	363,697	$	1,220,525

Contact:
Pall Corporation
Lisa McDermott, 516-801-9808

10